SCHEDULE: Sumitomo Mitsui Trust Group and Nikko Asset Management Disclose 5.4% Stake in 10x Genomics

Sumitomo Mitsui Trust Group, Inc. and Nikko Asset Management Co., Ltd. have jointly disclosed beneficial ownership of 5.4% of 10x Genomics, Inc.'s Class A common stock.

Summary

• Sumitomo Mitsui Trust Group, Inc. and Nikko Asset Management Co., Ltd., both Japanese financial institutions, have filed a Schedule 13G with the SEC.
• They collectively report beneficial ownership of 6,013,989 shares of 10x Genomics, Inc.'s Class A common stock.
• This ownership represents 5.4% of the total Class A common stock outstanding.
• The shares are primarily held through their subsidiaries, including Nikko Asset Management Americas, Inc. and Sumitomo Mitsui Trust Asset Management Co., Ltd.
• The filing certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of 10x Genomics, Inc.

Sentiment

Score: 6

Explanation: The filing indicates that two significant Japanese financial institutions have taken a substantial passive stake in 10x Genomics, suggesting a vote of confidence in the company's long-term prospects.

Positives

• Significant institutional investment from two major Japanese financial groups, indicating confidence in 10x Genomics.
• The acquisition of shares was for ordinary course of business, not for control, suggesting a passive investment.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

10x Genomics operates in the biotechnology and life sciences sector, specializing in genomics technologies. The investment by these financial institutions suggests continued interest in the growth potential of companies within this innovative industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be viewed positively, potentially increasing investor confidence and liquidity.

Key Dates

Keywords

10x Genomics, Sumitomo Mitsui Trust Group, Nikko Asset Management, beneficial ownership, Schedule 13G, institutional investment, Class A common stock, biotechnology, life sciences, genomics